Romosozumab
- Generic Name
- Romosozumab
- Brand Names
- Evenity 210 Mg Dose, Evenity
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 909395-70-6
- Unique Ingredient Identifier
- 3VHF2ZD92J
- Background
Romosozumab is a humanized monoclonal antibody indicated for the treatment of osteoperosis in postmenopausal women at high risk of fracture and patients who have failed in other treatments or are intolerant to other osteoperosis therapies. Romosozumab prevents bone resorption and induces the formation of bone though it is associated with an increased risk of...
- Indication
Romosozumab is indicated for the treatment of osteoporosis in post menopausal women at high risk of fractures and also in patients with osteoperosis who are intolerant to other treatments or who have failed in other treatments.
- Associated Conditions
- Osteoporosis
- Associated Therapies
- -
Combined Anabolic Therapy
- Conditions
- Interventions
- First Posted Date
- 2024-08-16
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT06558188
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Romosozumab As an Adjunct to Physiologic Estrogen Replacement in Functional Hypothalamic Amenorrhea
- Conditions
- Interventions
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 114
- Registration Number
- NCT06533865
Romosozumab Versus Denosumab in GIOP: a 2-year Extension Study
- Conditions
- Interventions
- First Posted Date
- 2024-06-24
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Tuen Mun Hospital
- Target Recruit Count
- 63
- Registration Number
- NCT06472050
- Locations
- 🇨🇳
Department of Medicine, Tuen Mun Hospital, Hong Kong, China
Sequential Therapies After Osteoanabolic Treatment
- Conditions
- Interventions
- First Posted Date
- 2023-12-11
- Last Posted Date
- 2023-12-15
- Lead Sponsor
- 424 General Military Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT06164795
- Locations
- 🇩🇪
Department of Medicine III and Center for Healthy Aging, Technische Universität Dresden, Dresden, Germany
🇬🇷251 Airforce & VA General Hospital, Athens, Greece
🇬🇷424 General Military Hospital, Thessaloniki, Greece
A Study of Romosozumab (EVENITY®) in Postmenopausal Women in India With Osteoporosis at a High Risk of Fracture.
- First Posted Date
- 2023-10-12
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Amgen
- Target Recruit Count
- 100
- Registration Number
- NCT06079476
- Locations
- 🇮🇳
Sir Ganga Ram Hospital, New Delhi, Delhi, India
🇮🇳Apollo Hospital, New Delhi, Delhi, India
🇮🇳Stavya Spine Hospital and Research Institute SSHRI, Ahmedabad, Gujarat, India
The Optimised Use of Romozosumab Study
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2023-10-25
- Lead Sponsor
- University of Aarhus
- Target Recruit Count
- 270
- Registration Number
- NCT06059222
- Locations
- 🇩🇰
Department of Endrocinology and Internal Medicine, Aarhus, Denmark
Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta
- Conditions
- Interventions
- First Posted Date
- 2023-08-02
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Amgen
- Target Recruit Count
- 106
- Registration Number
- NCT05972551
- Locations
- 🇯🇵
Okayama University Hospital, Okayama-shi, Okayama, Japan
🇯🇵Osaka Womens and Childrens Hospital, Izumi-shi, Osaka, Japan
🇯🇵National Center for Child Health and Development, Setagaya-ku, Tokyo, Japan
A Study of Romosozumab in Women With Multiple Myeloma and Osteoporosis
- First Posted Date
- 2023-03-20
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 10
- Registration Number
- NCT05775094
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
Treatment With Romosozumab Versus Denosumab to Improve Bone Mineral Density and Architecture in Subacute SCI
- Conditions
- Interventions
- First Posted Date
- 2021-10-29
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- James J. Peters Veterans Affairs Medical Center
- Target Recruit Count
- 40
- Registration Number
- NCT05101018
- Locations
- 🇺🇸
Kessler Institute for Rehabilitation, West Orange, New Jersey, United States
🇺🇸James J. Peters VA Medical Center, Bronx, New York, United States
A Study to Test the Efficacy, Safety and Tolerability of Romosozumab Treatment in Postmenopausal Chinese Women With Osteoporosis
- First Posted Date
- 2021-10-05
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 327
- Registration Number
- NCT05067335
- Locations
- 🇨🇳
Op0002 20199, Rui'an, China
🇨🇳Op0002 20130, Beijing, China
🇨🇳Op0002 20117, Guangzhou, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.